Text consolidated by Valsts valodas centrs (State
Language Centre) with amending regulations of:
12 May 2009 [shall come
into force from 16 May 2009];
3 November 2009 [shall come into force from 28 November
2009];
17 May 2011 [shall come into force from 21 May
2011];
12 June 2012 [shall come into force from 16 August
2012];
11 December 2012 [shall come into force from 23 February
2013];
21 May 2013 [shall come into force from 24 May
2013];
19 August 2014 [shall come into force from 23 August
2014];
26 May 2015 [shall come into force from 1 June
2015];
26 April 2016 [shall come into force from 1 May
2016];
7 March 2017 [shall come into force from 17 March
2017];
10 October 2017 [shall come into force from 16 October
2017].
If a whole or part of a paragraph has been amended,
the date of the amending regulation appears in square
brackets at the end of the paragraph. If a whole
paragraph or sub-paragraph has been deleted, the date of
the deletion appears in square brackets beside the
deleted paragraph or sub-paragraph.
|
|
Republic of Latvia
Cabinet
Regulation No. 847
Adopted 8 November 2005
|
Regulations
Regarding Narcotic Substances, Psychotropic Substances and
Precursors to be Controlled in Latvia
Issued pursuant
to
Section 3, Paragraph two of the law On Procedures for the Legal
Trade
of Narcotic and Psychotropic Substances and Medicinal
Products
1. This Regulation prescribes narcotic substances,
psychotropic substances and precursors to be controlled in
Latvia.
2. The following shall be controlled in Latvia in accordance
with the laws and regulations governing the circulation of
narcotic and psychotropic medicinal products and substances:
2.1. prohibited especially dangerous narcotic substances and
equivalent psychotropic substances and plants (Schedule I of
Narcotic Substances, Psychotropic Substances and Precursors to be
Controlled in Latvia) (Annex 1);
2.2. very dangerous narcotic substances and equivalent
psychotropic substances permitted for medical and scientific use
(Schedule II of Narcotic Substances, Psychotropic Substances and
Precursors to be Controlled in Latvia) (Annex 2);
2.3. dangerous psychotropic substances that can be abused
(Schedule III of Narcotic Substances, Psychotropic Substances and
Precursors to be Controlled in Latvia) (Annex 3);
2.4. derivatives, isomers, structural analogues, active
metabolites, esters, ethers, and salts (also salts of isomers,
structural analogues, active metabolites, esters, and ethers) of
the narcotic substances and psychotropic substances included in
Schedule I, II or III of Narcotic Substances, Psychotropic
Substances and Precursors to be Controlled in Latvia, as well as
medicinal products that contain the narcotic and psychotropic
substances included in the abovementioned Schedules, unless
exceptions are specified in laws and regulations;
2.5. the precursors referred to in Council Regulation (EC) No
111/2005 of 22 December 2004 laying down rules for the monitoring
of trade between the Community and third countries in drug
precursors and in Annexes to Regulation (EC) No 273/2004 of the
European Parliament and of the Council of 11 February 2004 on
drug precursors;
2.6. parts of plants, dried plants, pressed plants, powders,
tablets, capsules, extracts, tinctures and any other products of
the abovementioned plants that contain the substances included in
the Schedule I of Narcotic Substances, Psychotropic Substances
and Precursors to be Controlled in Latvia, except products that
are allowed for distribution in accordance with the laws and
regulations regarding food handling.
[12 May 2009; 3 November 2009; 26
May 2015; 7 March 2017]
2.1 The State Agency of Medicines shall notify
regarding changes in Schedules I, II and III of Narcotic
Substances, Psychotropic Substances and Precursors to be
Controlled in Latvia by publishing the information on the website
of the State Agency of Medicines (http://www.zva.gov.lv).
[17 May 2011]
3. Cabinet Regulation No. 35 of 20 January 2004, Regulations
regarding Schedules of Narcotic Substances, Psychotropic
Substances and Precursors to be Controlled in Latvia (Latvijas
Vēstnesis, 2004, No. 12), is repealed.
4. Sub-paragraph 7.18 of Annex 1 to this Regulation shall come
into force on 1 January 2012.
[17 May 2011]
5. Paragraph 5 of Annex 2 to this Regulation shall come into
force on 1 June 2011.
[17 May 2011]
Acting for the Prime Minister, Minister
for Justice S. Āboltiņa
Minister for Health G. Bērziņš
Annex 1
Cabinet
Regulation No. 847
8 November 2005
[11 December
2012; 21 May 2013; 19 August 2014; 26 May 2015; 26 April 2016; 7
March 2017; 10 October 2017]
Narcotic
Substances, Psychotropic Substances and Precursors to be
Controlled in Latvia
Schedule I
(Prohibited especially dangerous
narcotic substances, equivalent psychotropic substances and
plants, illegal handling and abuse of which endangers health)
1. Substances and plants classified in conformity with the
Single Convention on Narcotic Drugs of 30 March 1961:
1.1. synthetic opioid analgesics:
|
No.
|
International non-proprietary
name (INN)/trivial name
|
Number in the Chemical
Abstracts Service
(hereinafter - CAS No.)
|
Chemical name
|
|
1.1.1.
|
alphacetylmethadol (INN)
|
1553-31-7
|
[(3R*,6R*)-6-dimethylamino-4,4-di(phenyl)heptan-3-yl]
acetate |
|
1.1.2.
|
MPPP, desmethylprodine
|
13147-09-6
|
(4-phenyl-1-methylpiperidin-4-yl)propanoate |
|
1.1.3.
|
PEPAP
|
64-52-8
|
4-phenyl-1-(2-phenylethyl)piperidin-4-yl acetate |
|
1.1.4.
|
AH-7921
|
55154-30-8
|
3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide |
|
1.1.5.
|
U-47700
|
82657-23-6
|
3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide |
|
1.1.6.
|
U-51754
|
121279-74-1
|
2-(3,4-dichlorophenyl)-N-[2-(dimethylamino)cyclohexyl]-N-methylacetamide |
1.2. morphinan derivatives:
|
No.
|
International non-proprietary
name (INN)/trivial name
|
CAS No.
|
Chemical name
|
|
1.2.1.
|
heroin, morphine diacetate
(INN)
|
561-27-3
|
(5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
diacetate |
|
2.2.1.
|
desomorphine,
Krokodil
|
427-00-9
|
4,5-α-epoxy-17-methylmorphinan-3-ol |
|
1.3.2.
|
etorphine, Immobilon,
M99
|
14521-96-1
|
(5alpha,7alpha)-7-(2-hydroxypentan-2-yl)-6-methoxy-17-methyl-4,5-epoxy-6,14-ethenomorphinan-3-ol |
|
1.2.4.
|
acetorphine
|
25333-77-1
|
4,5α-epoxy-7α-(1-hydroxy-1-methylbutyl)-6-methoxy-17-methyl-6,14-endoetheno-morphinan-3-yl
acetate |
1.3. [10 October 2017]
1.4. products of plant origin with narcotic effect:
|
No.
|
Name
|
| 1.4.1. |
raw opium |
| 1.4.2. |
poppy straw |
| 1.4.3. |
preparations which are
manufactured from any type of poppy if they contain
narcotically active opium alkaloids: morphine, codeine,
thebaine (extracts, infusions and brews with active substance
content in any amount) |
| 1.4.4. |
cannabis, cannabis resin, oil,
extracts and tinctures |
| 1.4.5. |
coca leaf |
2. Substances and plants classified in conformity with the
Convention on Psychotropic Substances of 21 February 1971:
2.1. phenethylamine derivatives:
|
No.
|
International non-proprietary
name (INN)/trivial name
|
CAS No.
|
Chemical name
|
|
2.1.1.
|
mescaline
|
54-04-6
|
2-(3,4,5-trimethoxyphenyl)ethanamine |
|
2.1.2.
|
fenethylline
|
3736-08-1
|
(RS)-1,3-dimethyl-7-[2-(1-phenylpropan-2-ylamino)ethyl]purine-2,6-dione |
|
2.1.3.
|
fenproporex
|
16397-28-7
|
3-(1-phenylpropan-2-ylamino)propanenitrile |
|
2.1.4.
|
phentermine
|
122-09-8
|
2-methyl-1-phenylpropan-2-amine |
|
2.1.5.
|
mefenorex, Rondimen,
Pondinil, Anexate
|
17243-57-1
|
3-chloro-N-(1-phenylpropan-2-yl)propan-1-amine |
|
2.1.6.
|
4-methylaminorex
|
(±)-cis
isomers-29493-77-4
|
4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine |
|
2.1.7.
|
4,4′-DMAR
|
1445569-01-6
|
4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine |
2.2. natural substances and derivatives thereof:
|
No.
|
International non-proprietary
name (INN)/trivial name
|
CAS No.
|
Chemical name
|
|
2.2.1.
|
[7 March 2017] |
|
2.2.2.
|
7-hydroxymitragynine
|
174418-82-7
|
(αE,2S,3S,7aS,12bS)-3-Ethyl-1,2,3,4,6,7,7a,12b-octahydro-7a-hydroxy-8-methoxy-α-(methoxymethylene)indolo[2,3-a]quinolizine-2-acetic
acid methyl ester |
|
2.2.3.
|
mitragynine
|
6202-22-8
|
(E)-2-[(2S,3S)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[3,2-h]quinolizin-2-yl]-3-methoxyprop-2-enoic
acid methyl ester |
|
2.2.4.
|
salvinorin A
|
83729-01-5
|
(2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2H-benzo[f]isochromene-7-carboxylate |
|
2.2.5.
|
psilocin, psilotsin
|
520-53-6
|
3-[2-(dimethylamino)ethyl]-1H-indol-4-ol |
|
2.2.6.
|
psilocybin
|
520-52-5
|
[3-(2-Dimethylaminoethyl)-1H-indol-4-yl] dihydrogen
phosphate |
2.3. compounds of other substances:
|
No.
|
International non-proprietary
name (INN)/trivial name
|
CAS No.
|
Chemical name
|
|
2.3.1.
|
tenocyclidine TCP
|
21500-98-1
|
1-(1-(2-thienyl)cyclohexyl)piperidine |
|
2.3.2.
|
eticyclidine PCE
|
2201-15-2
|
N-ethyl-1-phenylcyclohexanamine |
|
2.3.3.
|
rolicyclidine, PHP, PCPY
|
2201-39-0
|
1-(1-phenylcyclohexyl)pyrrolidine |
|
2.3.4.
|
amineptine
|
57574-09-1
|
7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)amino]heptanoic
acid |
|
2.3.5.
|
cathine
|
492-39-7
|
(1S,2S)-2-amino-1-phenylpropan-1-ol |
|
2.3.6.
|
CRA-13
|
432047-72-8
|
1-naphthyl[4-(pentyloxy)-1-naphthyl]methanone |
|
2.3.7.
|
dichloropane
|
146725-34-0
|
methyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane-4-carboxylate |
2.4. plant products with psychotropic effect:
|
No.
|
Name
|
|
2.4.1.
|
catha
edulis |
|
2.4.2.
|
leonotis leonurus |
|
2.4.3.
|
mitragyna speciosa (kratom) |
|
2.4.4.
|
nymphaea caerulea |
|
2.4.5.
|
salvia divinorum |
|
2.4.6.
|
ephedra plant |
|
2.4.7.
|
hallucinogenic mushrooms |
2.5. psychotropic substances corresponding to the
description*:
|
No.
|
Name
|
|
2.5.1.
|
2,5-dimethoxyphenyl-ethanamines
2,5-dimethoxyphenyl-ethanamine and any compound derived
from 2- (2,5-dimethoxyphenyl)ethanamine:
a) by replacing hydrogen atom(s) on the benzene ring
with one or several identical or different substitutes or
substitutes which form a cyclic structure supplementing the
benzene ring;
b) by replacing hydrogen atom(s) in an ethylene group
with one or several alkyl groups;
c) by replacing one or two hydrogen atoms at the
nitrogen atom with a not-replaced or replaced alkyl group
or by including nitrogen atom in the atom cycle;
d) in any of the abovementioned compounds by replacing a
hydrogen atom at the nitrogen atom, if it is free, with a
not-replaced or replaced hydroxyl group or an acyl
group
|
|
2.5.2.
|
3,4-methylenedioxyphenylethanamines
3,4-methylenedioxyphenylethanamine and any compound
derived from 2-(3,4-methylenedioxyphenyl)ethanamine:
a) by replacing hydrogen atom(s) on the benzene ring
with one or several identical or different substitutes or
substitutes which form a cyclic structure supplementing the
benzene ring;
b) by replacing hydrogen atom(s) in an ethylene group
with one or several alkyl groups;
c) by replacing one or two hydrogen atoms at the
nitrogen atom with a not-replaced or replaced alkyl group
or by including nitrogen atom in the atom cycle;
d) in any of the abovementioned compounds by replacing a
hydrogen atom at the nitrogen atom, if it is free, with a
not-replaced or replaced hydroxyl group or an acyl
group
|
|
2.5.3.
|
Amphetamines
1-phenylpropan-2-amine, its enantiomers and any compound
derived from them:
a) by not replacing or by replacing one or two hydrogen
atoms at the nitrogen atom with not-replaced or replaced
alkyl group or including a nitrogen atom in the atom
cycle;
b) by changing the benzene ring in the compounds
referred to in Sub-paragraph "a" with another cyclic
structure, different from the benzene ring, which may be
replaced;
c) by replacing hydrogen atoms on the benzene ring of
the compounds referred to in Sub-paragraph "a" with one or
several identical or different substitutes or substitutes
which form a cyclic structure supplementing the benzene
ring;
d) by replacing one or several propyl group hydrogen
atoms in any of the abovementioned compounds with
not-replaced or replaced alkyl group or substitutes which
form a benzene ring or a cyclic structure supplementing the
cyclic structure referred to in Sub-Paragraph "b";
e) in any of the abovementioned compounds by replacing a
hydrogen atom at the nitrogen atom, if it is free, with a
not-replaced or replaced hydroxyl group or an acyl
group
|
|
2.5.4.
|
2-aminoindanes
2-aminoindane or any compound derived from
2-aminoindane:
a) by replacing hydrogen atoms on the benzene ring with
one or several identical or different substitutes or
substitutes which form a cyclic structure supplementing the
benzene ring;
b) by replacing one or two amino group hydrogen atoms
with a not-replaced or replaced alkyl group or by including
a nitrogen atom in the atom cycle
|
|
2.5.5.
|
Cyclic derivatives of 2-(2,5-dioxyphenyl)ethanamine
Any compound derived from
2-(2,5-dioxyphenyl)ethanamine:
a) in the condition 4 of hydrogen atoms by replacing
with alkyl group, haloalkane group or halogen atom;
b) in addition by replacing hydrogen atom of one
hydroxyl group with alkylen group or alkenylen group formed
by cycle of 5 or 6 members with the benzene ring in
ortho-condition;
c) in addition by replacing hydrogen atom of a second
hydroxyl group with alkylen group or alkenylen group formed
by cycle of 5 or 6 members with the benzene ring in
ortho-condition, or methyl group;
d) in addition by not replacing or replacing one or two
amino group hydrogen atoms or by including in the nitrogen
atom cycle;
e) in addition by not replacing or replacing one or
several ethylene group hydrogen atoms with a not-replaced
or replaced alkyl group
|
|
2.5.6.
|
Cathinones
2-amino-1-phenylpropan-1-one and any compound derived
from 2-amino-1-phenylpropan-1-one:
a) by not replacing or by replacing one or two hydrogen
atoms at the nitrogen atom with not-replaced or replaced
alkyl or alkoxy group or by including a nitrogen atom in
the atom cycle;
b) by not replacing or by replacing one or two hydrogen
atoms in propanone condition 3 with a not-replaced or
replaced alkyl group or alkoxy group or amino group;
c) by changing the benzene ring in the compounds
referred to in Sub-paragraph "a" or "b" with another cyclic
structure, different from the benzene ring, which may be
replaced;
d) by replacing hydrogen atoms on the benzene ring in
any of the compounds referred to in Sub-paragraph "a" or
"b" with one or several identical or different substitutes
or substitutes which form a cyclic structure supplementing
the benzene ring;
e) derivatives of any of the abovementioned compound
carbonyl group or amino group, or both
|
|
2.5.7.
|
Piperazines
Any compound derived from piperazine:
a) by replacing a hydrogen atom at one nitrogen atom
with a not-replaced or replaced phenyl group, not-replaced
or replaced benzyl group or cyclohexyl group;
b) by not replacing or by replacing the hydrogen atom at
a second nitrogen atom with a not-replaced or replaced
methyl group
|
|
2.5.8.
|
Tryptamines and beta-(benzofuran-3-yl)ethanamines
Any derivative of beta-(indol-3-yl)ethanamine or
beta-(benzofuran-3-yl)ethanamine**** which contains at
least one substitute from rows "a", "b" and "c":
a) where hydrogen atom(s) on the benzene ring has (have)
been replaced with one or several identical or different
substitutes or substitutes which form a cyclic structure
supplementing the benzene ring;
b) where hydrogen atoms in the ethylene group have been
replaced with a not-replaced or replaced alkyl group;
c) where one or two hydrogen atoms in the amino group
have been replaced with a not-replaced or replaced alkyl
group, or a nitrogen atom has been included in the
cycle
|
|
2.5.9.
|
1-Arylcyclohexylamines and
(1-arylcyclohexyl)methanamines
1-arylcyclohexylamines (except ketamine) and
(1-arylcyclohexyl)methanamines where the aryl group is a
not-replaced or replaced benzene or thiophene cycle, one or
two hydrogen atoms in the amino group have been replaced
with a not-replaced or replaced alkyl group, or a nitrogen
atom has been included in the cycle, and the cyclohexane
cycle is not replaced or replaced with a carbonyl group,
hydroxy group, alkoxy group or alkyl group
|
|
2.5.10.
|
Dibenzopyrans
Compounds derived from cannabinol*** modified on the
ring A, replaced on the ring B, their homologues with
different number of carbon atoms in the substitute in
condition 3, cis-, trans- and optical isomers thereof, as
well as their derivatives of hydroxyl group and halogen
derivatives
|
|
2.5.11.
|
Cyclohexylphenols
Any compound derived from
2-(3-hydroxycyclohexyl)phenol:
a) by replacing hydrogen atom in condition 5 of phenol
cycle;
b) in addition by not replacing or by replacing one or
several hydrogen atoms in the cyclohexyl group
|
|
2.5.12.
|
Naphthylideneindenes and naphthylmethylindenes
Any compound derived from 1-naphthylideneindene or
1-naphthylmethylindene:
a) by not replacing or by replacing a hydrogen atom at
indene C3 atom;
b) in addition by not replacing or by replacing in the
compounds referred to in Sub-paragraph "a" one or several
hydrogen atoms in the naphthyl group;
c) in addition by not replacing or by replacing in the
compounds referred to in Sub-paragraph "a" or "b", or both,
one or several hydrogen atoms in the indene cycle
|
|
2.5.13.
|
Naphthylmethylindoles
Any compound derived from
(indol-3-yl)(naphth-1-yl)methane:
a) by not replacing or by replacing a hydrogen atom at
the indole nitrogen atom;
b) in addition by not replacing or by replacing in the
compounds referred to in Sub-paragraph "a" one or several
hydrogen atoms in the naphthyl group;
c) in addition by not replacing or by replacing in the
compounds referred to in Sub-paragraph "a" or "b", or both,
one or several hydrogen atoms in the indole cycle
|
|
2.5.14.
|
Napthoylpyrroles
Any compound derived from 3-(1-naphthoyl)pyrrole:
a) by not replacing or by replacing a hydrogen atom at
the pyrrole nitrogen atom;
b) in addition by not replacing or by replacing in the
compounds referred to in Sub-paragraph "a" one or several
hydrogen atoms in pyrrole cycle;
c) in addition by not replacing or by replacing in the
compounds referred to in Sub-paragraph "a" or "b", or both,
one or several hydrogen atoms in the naphthoyl group
|
|
2.5.15.
|
Derivatives of indole, azaindole and
indazole-3-carbonyl
Derivatives of indole-3-carbonyl, derivatives of
azaindol-3-carbonyl, and derivatives of indazole-3-carbonyl
which are replaced at indole, azaindol or indazole cycle in
condition 1 of the nitrogen atom with a not-replaced or
replaced alkyl group and in condition 3 replaced at
carbonyl group with:
• a not-replaced or replaced alkyl group or a cycloalkyl
group;
• a not-replaced or replaced aromatic or heteroaromatic
cycle;
• a not-replaced or replaced alcoxy group, aryloxy
group, heteryloxy group;
• a replaced amino group
and in the indole or azaindol cycle condition 2
not-replaced or replaced with an alkyl group, and any of
the abovementioned compounds which has additionally been
replaced in an indole, azaindol or indazole cycle,
including such where the substitute makes an additional
cycle
|
|
2.5.16.
|
Benzimidazoles
Any compound derived from benzimidazole:
a) by replacing a hydrogen atom at the nitrogen atom
with a not-replaced or replaced alkyl group or a
not-replaced or replaced aroyl group;
b) in addition by replacing a hydrogen atom at the
nitrogen atom of the imidazole cycle with a not-replaced or
replaced (hetero)aryl group or a not-replaced or replaced
aroyl group;
c) in addition by not replacing or replacing hydrogen
atoms on the benzene ring of benzimidazole
|
|
2.5.17.
|
Diphenylethanamines
1,2-diphenylethan-1-amine, its enantiomers and any
compound derived from them:
a) by not replacing or by replacing hydrogen atoms on
one or both benzene rings with one or several identical or
different substitutes;
b) in addition by not replacing or by replacing in the
compounds referred to in Sub-paragraph "a" one or both
hydrogen atoms of the amino group with a not-replaced or
replaced alkyl group or by including it in the cycle;
c) in addition by replacing in the compounds referred to
in Sub-paragraph "b" one carbon atom on one or both benzene
rings with a nitrogen atom
|
|
2.5.18.
|
Derivatives of carbazole-3-carbonyl
Derivatives of carbazole-3-carbonyl that have been
replaced at the carbazole ring in oxygen atom condition 1
with a not-replaced or replaced alkyl group
and condition 3 at carbonyl group is replaced with:
a) a not-replaced or replaced alkyl group, cycloalkyl
group;
b) a not-replaced or replaced aromatic or heteroaromatic
cycle;
c) a not-replaced or replaced alcoxy group, aryloxy
group, heteryloxy group;
d) a replaced amino group
and any of the abovementioned compounds that has been
additionally replaced in the carbazole ring
|
|
2.5.19.
|
Derivatives of pyrazole-3-carbonyl
Derivatives of pyrazole-3-carbonyl which in condition 3
at carbonyl group are replaced with:
• a not-replaced or replaced alkyl group or a cycloalkyl
group;
• a not-replaced or replaced aromatic or heteroaromatic
cycle;
• a not-replaced or replaced alcoxy group, aryloxy
group, heteryloxy group;
• a replaced amino group
and in pyrazole cycle conditions 1 and 4 (one or both)
not replaced or replaced with not-replaced or replaced
alkyl groups or aryl groups and in condition 5 replaced
with a not-replaced or replaced aryl group
|
|
2.5.20.
|
Derivatives of pyrazole-5-carbonyl
Derivatives of pyrazole-5-carbonyl which in condition 5
at carbonyl group are replaced with:
• a not-replaced or replaced alkyl group or a cycloalkyl
group;
• a not-replaced or replaced aromatic or heteroaromatic
cycle;
• a not-replaced or replaced alcoxy group, aryloxy
group, heteryloxy group;
• a replaced amino group
and in pyrazole cycle conditions 1 and 4 (one or both)
not replaced or replaced with not-replaced or replaced
alkyl groups or aryl groups and in condition 3 replaced
with a not-replaced or replaced aryl group
|
|
2.5.21.
|
2-phenylmorpholines
2-phenylmorpholine, its enantiomers and any compound
derived from them:
a) by changing the benzene ring with a thiophene or
pyridine ring;
b) by changing the morpholine cycle with a
thiomorpholine cycle;
c) by replacing one or several hydrogen atoms on the
benzene, thiophene or pyridine ring with a not-replaced or
replaced alkyl group, alcoxy group, amide group, amino
group, sulphonyl group or substitutes which form a cyclic
structure supplementing the benzene, thiophene or pyridine
ring;
d) by replacing one or several hydrogen atoms on the
benzene, thiophene or pyridine ring with a hydroxyl group
or halogen atom;
e) by replacing one or several hydrogen atoms on a
morpholine or thiomorpholine cycle with a hydroxyl group,
nitroso group, carbonyl group or not-replaced or replaced
alkyl group
|
|
2.5.22.
|
Lysergamides (or amides of lysergic acid)
4,6,6a,7,8,9-hexahydroindol[4,3-fg]quinoline-9-carboxamide*****,
its enantiomers and any compound derived from them:
a) by not replacing or by replacing one or two hydrogen
atoms at the nitrogen atom in an amide group with
not-replaced or replaced alkyl group(s) or substitutes that
include a nitrogen atom in the atom cycle;
b) by not replacing or by replacing the hydrogen atom at
the nitrogen atom in a hydrogenated quinoline cycle with a
not-replaced or replaced alkyl group;
c) by not replacing or by replacing the hydrogen atom at
the nitrogen atom in the indole cycle with a not-replaced
or replaced alkyl group
|
|
2.5.23.
|
Derivatives of indoline-2-one-3-hydrazine carbonyl
Derivatives of indole-2-one-3-hydrazine carbonyl which
are replaced at the nitrogen atom in indoline-2-one cycle
with a not-replaced or replaced alkyl group and in
condition 3 replaced at carbonyl group with:
• a not-replaced or replaced alkyl group or a cycloalkyl
group;
• a not-replaced or replaced aromatic or heteroaromatic
cycle;
• a not-replaced or replaced alcoxy group, aryloxy
group, heteryloxy group;
• a replaced amino group;
and any of the abovementioned compounds in which
hydrazine group hydrogen atom is replaced with an alkyl
group, or replaced in indoline-2-one cycle
|
|
2.5.24.
|
Gamma-carbonyl-1-ones
Any compound derived from
2,5-dihydro-1H-pyrido[4,3-b]indolo-1-one:
a) by replacing hydrogen atom in condition 5 with a
not-replaced or replaced alkyl group or a cycloalkyl
group;
b) by replacing hydrogen atom in condition 2 with a
not-replaced or replaced alkyl group, cycloalkyl group, a
not-replaced or replaced aromatic or heteroaromatic cycle,
and any of the abovementioned compounds that has been
additionally replaced in the carboline cycle
|
|
2.5.25.
|
Acetylfentanyls
N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide
and any compound derived from
N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, if
one or several conditions have been met:
a) by replacing one or several hydrogen atoms on one or
both benzene rings with one or several identical or
different halogen atoms or alcoxy groups;
b) by replacing one or several hydrogen atoms in
piperidine cycle condition 2, 3, 5, or 6 with a
not-replaced or replaced alkyl group;
c) by replacing one or several ethylene group hydrogen
atoms with a not-replaced or replaced alkyl group or
hydroxyl group;
d) by replacing one or several hydrogen atoms in acetyl
group with a not-replaced or replaced alkyl group(s),
alkenyl group, methoxy group or by including a carbon atom
in a cycle which may be replaced, including by creating
supplementing cycles;
e) by replacing ethylene group with a methylene
group;
f) by replacing hydrogen atom in condition 5 of
piperidine cycle with a replaced or not-replaced phenyl
group or ester group;
g) by changing the benzene ring present in
N-(1-phenethylpiperidin-4-yl) group with another
cyclic structure, different from the benzene ring, which
may be replaced;
h) by changing the benzene ring of N-phenyl group with
another saturated structure, different from the benzene
ring, which may be replaced
|
Notes.
1. * If the substance is also referred to in Annex 2 or 3 to
this Regulation, it shall not be applicable to Annex 1.
2. ** Except ketamine.
3. *** Except cannabidiol.
4. **** Except serotonin, sumatriptan, zolmitriptan.
5. ***** Except ergometrine, ergotamine, methylergometrine,
methysergide.
Annex 2
Cabinet
Regulation No. 847
8 November 2005
[10 October
2017]
Narcotic
Substances, Psychotropic Substances and Precursors to be
Controlled in Latvia
Schedule II
(Very dangerous
narcotic substances and equivalent psychotropic substances
permitted for medical and scientific use)
1. Substances classified in conformity with Schedule I of the
Single Convention on Narcotic Drugs of 30 March 1961:
|
No.
|
International non-proprietary
name (INN)/trivial name
|
CAS No.
|
| 1.1. |
acetylmethadol |
509-74-0 |
| 1.2. |
alfentanil |
71195-58-9 |
| 1.3. |
allylprodine |
25384-17-2 |
| 1.4. |
alphameprodine |
468-51-9 |
| 1.5. |
alphamethadol |
17199-54-1 |
| 1.6. |
alphaprodine |
77-20-3 |
| 1.7. |
anileridine |
144-14-9 |
| 1.8. |
benzethidine |
3691-78-9 |
| 1.9. |
benzylmorphine |
14297-87-1 |
| 1.10. |
betacetylmethadol |
17199-59-6 |
| 1.11. |
betameprodine |
468-50-8 |
| 1.12. |
betamethadol |
17199-55-2 |
| 1.13. |
betaprodine |
468-59-7 |
| 1.14. |
bezitramide |
15301-48-1 |
| 1.15. |
dextromoramide |
357-56-2 |
| 1.16. |
diampromide |
552-25-0 |
| 1.17. |
diethylthiambutene |
86-14-6 |
| 1.18. |
difenoxin |
28782-42-5 |
| 1.19. |
dihydroetorphine |
14357-76-7 |
| 1.20. |
dihydromorphine |
509-60-4 |
| 1.21. |
dimenoxadol |
509-78-4 |
| 1.22. |
dimepheptanol |
545-90-4 |
| 1.23. |
dimethylthiambutene |
524-84-5 |
| 1.24. |
dioxaphetyl butyrate |
467-86-7 |
| 1.25. |
diphenoxylate |
915-30-0 |
| 1.26. |
dipipanone |
467-83-4 |
| 1.27. |
drotebanol |
3176-03-2 |
| 1.28. |
ecgonine, esters thereof and
derivatives which may be converted into ecognine and
cocaine |
481-37-8 |
| 1.29. |
ethylmethylthiambutene |
441-61-2 |
| 1.30. |
etoxeridine |
469-82-9 |
| 1.31. |
etonitazene |
911-65-9 |
| 1.32. |
phenadoxone |
467-84-5 |
| 1.33. |
phenampromide |
129-83-9 |
| 1.34. |
phenazocine |
127-35-5 |
| 1.35. |
phenomorphan |
468-07-5 |
| 1.36. |
phenoperidine |
562-26-5 |
| 1.37. |
fentanyl |
437-38-7 |
| 1.38. |
furethidine |
2385-81-1 |
| 1.39. |
hydrocodone |
125-29-1 |
| 1.40. |
hydromorphinol |
2183-56-4 |
| 1.41. |
hydromorphone |
466-99-9 |
| 1.42. |
hydroxypethidine |
468-56-4 |
| 1.43. |
isomethadone |
466-40-0 |
| 1.44. |
ketobemidone |
469-79-4 |
| 1.45. |
clonitazene |
3861-76-5 |
| 1.46. |
codoxime |
7125-76-0 |
| 1.47. |
cocaine |
50-36-2 |
| 1.48. |
levophenacylmorphan |
10061-32-2 |
| 1.49. |
levomethorphan |
125-70-2 |
| 1.50. |
levomoramide |
5666-11-5 |
| 1.51. |
levorphanol |
77-07-6 |
| 1.52. |
methadone |
76-99-3 |
| 1.53. |
methadone intermediate |
125-79-1 |
| 1.54. |
metazocine |
3734-52-9 |
| 1.55. |
methyldesorphine |
16008-36-9 |
| 1.56. |
methyldihydromorphine |
509-56-8 |
| 1.57. |
metopon |
143-52-2 |
| 1.58. |
moramide intermediate |
3626-55-9 |
| 1.59. |
morpheridine |
469-81-8 |
| 1.60. |
morphine |
57-27-2 |
| 1.61. |
morphine methobromide and other
morphine derivatives containing pentavalent nitrogen |
125-23-5 |
| 1.62. |
morphine-N-oxide |
639-46-3 |
| 1.63. |
myrophine |
467-18-5 |
| 1.64. |
nicomorphine |
639-48-5 |
| 1.65. |
noracymethadol |
1477-39-0 |
| 1.66. |
norlevorphanol |
1531-12-0 |
| 1.67. |
normethadone |
467-85-6 |
| 1.68. |
normorphine |
466-97-7 |
| 1.69. |
norpipanone |
561-48-8 |
| 1.70. |
oxycodone |
76-42-6 |
| 1.71. |
oxymorphone |
76-41-5 |
| 1.72. |
opium |
not specified |
| 1.73. |
pethidine |
57-42-1 |
| 1.74. |
pethidine intermediate A |
3627-62-1 |
| 1.75. |
pethidine intermediate B |
77-17-8 |
| 1.76. |
pethidine intermediate C |
3627-48-3 |
| 1.77. |
piminodine |
13495-09-5 |
| 1.78. |
piritramide |
302-41-0 |
| 1.79. |
proheptazine |
77-14-5 |
| 1.80. |
properidine |
561-76-2 |
| 1.81. |
racemethorphan |
510-53-2 |
| 1.82. |
racemoramide |
545-59-5 |
| 1.83. |
racemorphan |
297-90-5 |
| 1.84. |
remifentanil |
132875-61-7 |
| 1.85. |
sufentanil |
56030-54-7 |
| 1.86. |
thebacon |
466-90-0 |
| 1.87. |
thebaine |
115-37-7 |
| 1.88. |
tilidine |
20380-58-9 |
| 1.89. |
trimeperidine |
64-39-1 |
2. Substances classified in conformity with Schedule II of the
Single Convention on Narcotic Drugs of 30 March 1961:
|
No.
|
International non-proprietary
name (INN)/trivial name
|
CAS No.
|
| 2.1. |
acetyldihydrocodeine |
3861-72-1 |
| 2.2. |
dextropropoxyphene |
469-62-5 |
| 2.3. |
dihydrocodeine |
125-28-0 |
| 2.4. |
ethylmorphine |
76-58-4 |
| 2.5. |
pholcodine |
509-67-1 |
| 2.6. |
codeine |
76-57-3 |
| 2.7. |
nicocodine |
3688-66-2 |
| 2.8. |
nicodicodine |
808-24-2 |
| 2.9. |
norcodeine |
467-15-2 |
| 2.10. |
propiram |
15686-91-6 |
3. Substances classified in conformity with Schedule II of the
Convention on Psychotropic Substances of 21 February 1971:
|
No.
|
International non-proprietary
name (INN)/trivial name
|
CAS No.
|
| 3.1. |
zipeprol |
34758-83-3 |
| 3.2. |
dronabinol
(delta-9-tetrahydrocannabinol and its stereochemical
variants) |
1972- 08-3 (CAS No. indicated
for substance "dronabinol") |
| 3.3. |
phencyclidine (PCP) |
77-10-1 |
| 3.4. |
phenmetrazine |
134-49-6 |
| 3.5. |
mecloqualone |
340-57-8 |
| 3.6. |
methaqualone |
72-44-6 |
| 3.7. |
methylphenidate |
113-45-1 |
| 3.8. |
secobarbital |
76-73-3 |
| 3.9. |
gamma-hydroxybutyric acid
(GHB) |
591-81-1 |
| 3.10. |
methylmorphenate |
231299-92-6 |
4. Substances classified in conformity with Schedule III of
the Convention on Psychotropic Substances of 21 February
1971:
|
No.
|
International non-proprietary
name (INN)/trivial name
|
CAS No.
|
| 4.1. |
amobarbital |
57-43-2 |
| 4.2. |
buprenorphine |
52485-79-7 |
| 4.3. |
butalbital |
77-26-9 |
| 4.4. |
cyclobarbital |
52-31-3 |
| 4.5. |
flunitrazepam |
1622-62-4 |
| 4.6. |
glutethimide |
77-21-4 |
| 4.7. |
hexobarbital |
56-29-1 |
| 4.8. |
pentazocine |
359-83-1 |
| 4.9. |
pentobarbital |
76-74-4 |
5. Narcotic substance, illicit circulation and abuse of which
may endanger health
|
No.
|
International non-proprietary
name (INN)/trivial name
|
CAS No.
|
| 5.1. |
tapentadol |
175591-09-0 |
Annex 3
Cabinet
Regulation No. 847
8 November 2005
[10 October
2017]
Narcotic
Substances, Psychotropic Substances and Precursors to be
Controlled in Latvia
Schedule III
(Dangerous
psychotropic substances that can be abused)
Substances classified in conformity with Schedule IV of the
Convention on Psychotropic Substances of 21 February 1971:
|
No.
|
International non-proprietary
name (INN)/trivial name
|
CAS No.
|
| 1. |
Allobarbital |
52-43-7 |
| 2. |
Alprazolam |
28981-97-7 |
| 3. |
Amfepramone |
90-84-6 |
| 4. |
Aminorex |
2207-50-3 |
| 5. |
Barbital |
57-44-3 |
| 6. |
Benzfetamine |
156-08-1 |
| 7. |
Bromazepam |
1812-30-2 |
| 8. |
Brotizolam |
57801-81-7 |
| 9. |
Butobarbital |
77-28-1 |
| 10. |
Cephedrine |
67055-59-8 |
| 11. |
Delorazepam |
2894-67-9 |
| 12. |
Diazepam |
439-14-5 |
| 13. |
Ephedrine* |
299-42-3 |
| 14. |
Estazolam |
29975-16-4 |
| 15. |
Ethchlorvynol |
113-18-8 |
| 16. |
Ethinamate |
126-52-3 |
| 17. |
Ethyl loflazepate |
29177-84-2 |
| 18. |
Phenatine |
139-68-4 |
| 19. |
Fenazepam |
51753-57-2 |
| 20. |
Fencamfamin |
1209-98-9 |
| 21. |
Phendimetrazine |
634-03-7 |
| 22. |
Phenobarbital |
50-06-6 |
| 23. |
Fludiazepam |
3900-31-0 |
| 24. |
Flurazepam |
17617-23-1 |
| 25. |
Halazepam |
23092-17-3 |
| 26. |
Haloxazolam |
59128-97-1 |
| 27. |
Chlordiazepoxide |
58-25-3 |
| 28. |
Camazepam |
36104-80-0 |
| 29. |
Ketazolam |
27223-35-4 |
| 30. |
Clobazam |
22316-47-8 |
| 31. |
Cloxazolam |
24166-13-0 |
| 32. |
Clonazepam |
1622-61-3 |
| 33. |
Clorazepate |
23887-31-2 |
| 34. |
Clotiazepam |
33671-46-4 |
| 35. |
Lefetamine (SPA) |
7262-75-1 |
| 36. |
Loprazolam |
61197-73-7 |
| 37. |
Lorazepam |
846-49-1 |
| 38. |
Lormetazepam |
848-75-9 |
| 39. |
Mazindol |
22232-71-9 |
| 40. |
Medazepam |
2898-12-6 |
| 41. |
Meprobamate |
57-53-4 |
| 42. |
Methylphenobarbital |
115-38-8 |
| 43. |
Methyprylon |
125-64-4 |
| 44. |
Mesocarb |
34262-84-5 |
| 45. |
Midazolam |
59467-70-8 |
| 46. |
Nimetazepam |
2011-67-8 |
| 47. |
Nitrazepam |
146-22-5 |
| 48. |
Nordazepam |
1088-11-5 |
| 49. |
Oxazepam |
604-75-1 |
| 50. |
Oxazolam |
24143-17-7 |
| 51. |
Pemoline |
2152-34-3 |
| 52. |
Pinazepam |
52463-83-9 |
| 53. |
Pipradrol |
467-60-7 |
| 54. |
Pyrovalerone |
3563-49-3 |
| 55. |
Prazepam |
2955-38-6 |
| 56. |
Propanidid |
1421-14-3 |
| 57. |
Pseudoephedrine* |
90-82-4 |
| 58. |
Secbutabarbital |
125-40-6 |
| 59. |
Temazepam |
846-50-4 |
| 60. |
Tetrazepam |
10379-14-3 |
| 61. |
Tofisopam |
22345-47-7 |
| 62. |
Triazolam |
28911-01-5 |
| 63. |
Trihexyphenidyl |
144-11-6 |
| 64. |
Vinylbital |
2430-49-1 |
| 65. |
Zolpidem |
82626-48-0 |
| 66. |
Zopiclone |
43200-80-2 |
| 67. |
Tramadol |
27203-92-5 |
| 68. |
Derivative of alprazolam
triazolo-benzophenone |
Not available |
| 69. |
Deschloroetizolam |
40054-73-7 |
| 70. |
Metizolam |
40054-68-0 |
| 71. |
Nitrazolam |
28910-99-8 |
| 72. |
Pyrazolam |
39243-02-2 |
Note. * The procedures specified by regulatory enactments in
the field of pharmacy shall also be observed during control.
Translation © 2018 Valsts valodas centrs (State
Language Centre)
|
|
Saistītie dokumenti
-
Zaudējis spēku ar
-
Grozījumi
-
Tiesību akti, kuriem maina statusu
-
Izdoti saskaņā ar
-
Skaidrojumi
-
Citi saistītie dokumenti
|
